SCHEDULE: BVF Group Discloses 7.6% Stake in Sutro Biopharma

A group of entities associated with Biotechnology Value Fund and Mark N. Lampert reported beneficial ownership of 7.6% of Sutro Biopharma, Inc.'s common stock.

Summary

• Biotechnology Value Fund L.P. (BVF) and its affiliated entities, including Mark N. Lampert, collectively reported beneficial ownership of 1,251,788 shares of Sutro Biopharma, Inc. common stock.
• This aggregate ownership represents approximately 7.6% of the outstanding shares of Sutro Biopharma, Inc., based on 16,432,271 shares outstanding as of February 10, 2026.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing control of Sutro Biopharma, Inc., other than activities solely in connection with a nomination under Rule 14a-11.
• Individual entities within the group hold varying percentages: BVF holds 4.1% (668,693 shares), BVF2 holds 3.0% (488,916 shares), and Biotechnology Value Trading Fund OS LP holds 0.5% (75,359 shares).
• The filing is a Schedule 13G, which is typically filed by passive investors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it signifies a significant institutional investor's continued or new stake in Sutro Biopharma, which can be interpreted as a vote of confidence without implying any immediate operational changes or financial performance.

Positives

• A significant institutional investor group, Biotechnology Value Fund, maintains a substantial stake in Sutro Biopharma, potentially signaling confidence in the company's long-term prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors who acquire more than 5% of a company's stock. This filing indicates continued or new interest from a specialized biotechnology fund, which can be a positive signal for a biopharma company like Sutro Biopharma, suggesting a belief in its pipeline or market position within the competitive biotechnology sector.

Related Party Transactions

• The filing details a group of affiliated entities (Biotechnology Value Fund L.P., BVF I GP LLC, Biotechnology Value Fund II L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert) that are acting as a group to beneficially own shares in Sutro Biopharma, Inc. This constitutes a related party group for reporting purposes.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and potentially provide stability.
• Management: Awareness of a significant passive investor group holding a substantial stake.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a passive ownership stake by a group of institutional investors. While the significant stake by Biotechnology Value Fund could be seen as a positive signal of confidence, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental updates from Sutro Biopharma to make informed investment decisions.

Keywords

Sutro Biopharma, STRO, Biotechnology Value Fund, BVF, Mark N. Lampert, Schedule 13G, Beneficial Ownership, Institutional Investor, Biopharma, Common Stock